Global Incontinence Devices Market - 2023-2030

Global Incontinence Devices Market - 2023-2030

Market Overview

Incontinence Devices Market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 6.4% during the forecast period (2023-2030).

Incontinence refers to involuntary loss of urine from the bladder (urinary incontinence) or bowel motion, feces, or wind from the bowel (fecal or bowel incontinence). Urinary incontinence is a widespread medical condition that affects 200 million people worldwide. Urinary Incontinence is twice as common in women as in men.

Market Dynamics

The major factors driving the global incontinence devices market are an increase in chronic diseases such as overactive bladder or kidney stones globally, rising research and development expenditure and a surge in the geriatric population. An increase in novel product launches contributed to the growth of the incontinence devices market.

Increased incontinence associated with chronic conditions and technologically advanced product launches is expected to drive the market’s growth.

The rising research on these incontinence device products and the growth in the prevalence of bladder disorders such as overactive bladder in the geriatric population will drive the market growth. An increase in chronic diseases globally is also aiding market growth. Chronic kidney disease (CKD) is more common in people aged 65 years or older (38%) than in people aged 45–64 years (13%) or 18–44 years (7%), according to the Centers for Disease Control and Prevention (CDC). There has been an increase in R&D activities by many healthcare companies to develop novel, innovative and technologically advanced products.

The key factors boosting the market growth include the rise in the geriatric population that suffers from urological conditions, the increase in incontinence associated with chronic conditions such as kidney stones and the availability of innovative devices. Moreover, the increase in research and development of novel products and the availability of technologically advanced products by key players are also expected to play a vital role in the market’s growth.

Various novel product launches, regulatory approvals and research studies contribute to the market’s growth. For instance, in November 10, 2021, Caldera Medical, a medical device company developing surgical products for stress urinary incontinence treatment and Pelvic Organ Prolapse, announced its clearance for the novel Desara TVez for treating stress urinary incontinence. This launch further expands Cladera’s broadest product portfolio for women suffering from stress urinary incontinence treatment options.

The risks associated with incontinence surgery are expected to hamper the market’s growth.

However, the risks associated with incontinence surgery include temporary difficulty urinating, urinary tract infection, development of an overactive bladder, groin pain and surgical material sticking out into the vagina. These factors may hinder the growth of the market.

Lack of awareness is also a leading factor restraining the market’s growth. In low-income countries, people are unaware of incontinence device usage, and the unavailability of reimbursement scenarios hinders the market’s growth.

COVID-19 Impact Analysis

The pandemic has positively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The overactive bladder treatment market has experienced huge profits due to COVID. In covid patients, bladder-related problems such as overactive bladder were also observed. COVID affected the bladders of patients. Key manufacturers have started various research and clinical trials. Various initiatives, product launches, collaborations and mergers are happening worldwide, boosting the market’s growth. For instance, in July 2022, Urovant Sciences announced its license agreement with Pierre Fabre Medicament for Vibegron commercialization for overactive bladder treatment in European Areas.

Segment Analysis

The electrical stimulation devices segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The electrical stimulation devices segment is the highest market holder in the global incontinence devices market. The global incontinence devices market is segmented based on product type as urinary catheters, electrical stimulation devices, vaginal slings, and artificial urinary sphincters. The electrical stimulation device segment is the largest market shareholder due to its high demand, advantages and usage, rising adoption of these incontinence devices, better results in bladder disorder patients and increased research and development activities, which are expected to remain high during the forecast period.

The electrical stimulation device or neurostimulation device utilizes an electrode that is implanted under the skin to stimulate nerves with electricity around the bladder. The electric signals traveling from the bladder to the brain are blocked with electricity reducing the symptoms of an overactive bladder are blocked. These therapies are of two types: sacral neuromodulation and percutaneous tibial nerve stimulation.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market’s growth. For instance, in April 2021, Medtronic, the medical technology company, announced receiving approval from the United States Food and Drug Administration to continue the investigational device exemption trial for evaluating its implantable tibial neuromodulation device, an internally developed therapy specially developed for bladder incontinence symptom’s relief.

Geographical Analysis

North America holds the largest market share in the global incontinence devices market.

North America dominates the global incontinence devices market, primarily due to its large population, excellent medical infrastructure, and rising number of bladder-related disorders. The market is expected to grow at a relatively moderate pace during the forecast period due to healthcare expenditure in the US. The market’s significant size is attributed to the high medical expenditure. As per the National Association for Incontinence (NAFC), in North America, nearly 200 million people were affected by urinary incontinence in 2021. According to WomensHealth.gov, urinary incontinence is twice as common in men, whereas stress urinary incontinence is most common in pregnant women, giving birth and going through menopause.

Increasing expenditure on healthcare and raising awareness among people are also contributing to the market’s growth in this region. Advancement of products for different types of incontinence, including stress incontinence, urge incontinence, overflow incontinence, functional incontinence, increase in pharmaceutical establishment across the region, government approvals, and key players in the region are contributing to the growth of the incontinence devices market.

Moreover, the growing number of product launches is responsible for the market’s growth. Many key developments, regulatory approvals, technological advancements, collaborations, and agreements are taking place in this region. In Oct 2020, Essity health and hygiene company launched TENA SmartCare. It is a novel, reusable digital sensor for better incontinence care. It will be available for working professionals and home caregivers.

Competitive Landscape

The incontinence devices market is moderately competitive with local and global companies’ presence. B. Braun Melsungen AG, ConvaTec Inc., Coloplast Corp, BD, Promedon GmbH, Medtronic Plc, Wellspect HealthCare (Dentsply Sirona), Hollister Incorporated, A.M.I. GmbH, Caldera Medical and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in August 11, 2022, A.M.I. GmbH announced its partnership with Medistim Norge AS, an established provider of medical devices for Norwegian health institutions. This collaboration will extend Norge’s product portfolio in urogynecology, coloproctology, and urology and will provide products and solutions for incontinence, pelvic organ prolapses and hemorrhoid patients.

B. Braun Melsungen AG.

Overview: B. Braun is a company that manufactures medical and pharmaceuticals device. Headquartered in Melsungen, Germany and founded in 1839. They provide services in around 60 countries that employ around 63,000 people. They have around 5,000 varieties of healthcare products.

Product Portfolio:

Actreen Mini Cath: Actreen Mini Cath is a urinary catheter that is short and specially designed for the self-catheterization of females. It is a modern and feminine design and is ready to use as a catheter.

The global incontinence devices market report would provide access to approx.: 45+ market data tables, 40+ figures and 200 (approximate) pages.